Kevin Outterson

Kevin Outterson is the founding Executive Director of CARB-X, the world’s leading public-private partnership that accelerates the early-stage development of innovative products to prevent, diagnose and treat bacterial infections globally. Key partners in CARB-X include the US Government (BARDA & NIAID), Wellcome, the German Federal Ministry of Education and Research (BMBF), the UK Government (GAMRIF), the Novo Nordisk Foundation, the Public Health Agency of Canada (PHAC) and the Bill & Melinda Gates Foundation. CARB-X has supported more than 100 R&D projects around the world. 18 of these projects have already reached or surpassed first-in-human clinical trials, including two products already on the market. In 2020, CARB-X was awarded the Innovating for Impact Partnership Award by the Global Health Technologies Coalition (GHTC) for its work in accelerating antibacterial R&D. Kevin Outterson is also Austin B. Fletcher Professor of Law at Boston University, where he co-directs the Health Law Program. Professor Outterson has published almost 100 articles and book chapters (available at Google Scholar) on health care law, with a focus on incentive problems with antimicrobial resistance, including push and pull incentives for antimicrobials. He served as a senior author on many key research reports and expert panels on antibiotic innovation. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work.